Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) has announced its participation in the 97th Annual Western Veterinary Conference (WVC), scheduled for March 2-5, 2025, in Las Vegas. The conference, attracting approximately 20,000 veterinary professionals, will feature presentations about the company's Nu.Q® Vet Cancer Test.
The company will host three presentations by notable veterinary professionals: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes, and Dr. Tom Butera. These sessions will focus on various aspects of the Nu.Q® Vet Cancer Test, including cancer journey navigation, practical implementation, and early detection screening. The test is designed to detect seven common cancers in dogs and is marketed as accessible, affordable, and easy-to-use with rapid results.
Positive
- Strategic expansion of Nu.Q® Vet Cancer Test awareness in North American market
- Product capable of detecting 7 common canine cancers
- Large market exposure through 20,000 veterinary professionals at WVC
Negative
- None.
News Market Reaction – VNRX
In the trading session that priced this news, VNRX declined 3.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM
Representatives will also be available at exhibition booth #2943
In addition, the Volition team is hosting a meet and greet at exhibition booth #2943 showcasing the Company's Nu.Q® Vet Cancer Test.
Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC commented:
"We are delighted to showcase the Nu.Q® Vet Cancer Test to the veterinary community attending WVC this year. We continue our strategic commercialization efforts in
Featured Volition Events
Presentation 1
Date and Time: Monday, March 3, 2025, from 2:00PM - 2:50 PM
Topic: "Detect, Treat, Monitor: Navigating the Canine Cancer Journey with Nu.Q® Vet Cancer Test"
Speaker: Dr. Sue Ettinger, DVM, DACVIM (Oncology). Dr. Ettinger is known throughout the veterinary community as "Dr. Sue Cancer Vet."
Location: Ballroom F, Level 2
Presentation 2
Date and Time: Tuesday, March 4, 2025, from 10:30 AM - 11:00 AM
Topic: "Utilizing the Nu.Q® Vet Cancer Test in Practice"
Speaker: Dr. Brett Cordes, DVM
Location: Western Frontier, Learning Hub, Exhibit Hall Level 1
Presentation 3
Date and Time: Wednesday, March 5 from 12:10 PM -1:00 PM
Topic: "The Nu.Q® Vet Cancer Test - Early Detection with Canine Cancer Screening"
Speaker: Dr. Tom Butera, DVM
Location: Ballroom J, Level 2
About WVC
The WVC Annual Conference is one of the largest and longest-running veterinary conferences in the country. WVC offers hundreds of educational opportunities, including lectures, hands-on CE labs, and drop-in learning sessions.
The conference will take place this year at the Mandalay Bay Convention Center in
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-showcases-nuq-vet-cancer-test-at-the-97th-wvc-annual-conference-302387815.html
SOURCE VolitionRx Limited